PE20070317A1 - Agentes de union a esclerostina o fragmentos de esclerostina - Google Patents

Agentes de union a esclerostina o fragmentos de esclerostina

Info

Publication number
PE20070317A1
PE20070317A1 PE2006000459A PE2006000459A PE20070317A1 PE 20070317 A1 PE20070317 A1 PE 20070317A1 PE 2006000459 A PE2006000459 A PE 2006000459A PE 2006000459 A PE2006000459 A PE 2006000459A PE 20070317 A1 PE20070317 A1 PE 20070317A1
Authority
PE
Peru
Prior art keywords
seq
sclerostin
cdr
antibody
fragments
Prior art date
Application number
PE2006000459A
Other languages
English (en)
Inventor
Christopher Paszty
Kevin Graham
Kelly Sue Hoffmann
Alastair Lawson
Andy Popplewell
David Winkler
Aaron George Winters
Wenyan Shen
Hsieng Sen Lu
John Latham
Alistair James Henry
Martyn Kim Robinson
Original Assignee
Ucb Sa
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070317(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Sa, Amgen Inc filed Critical Ucb Sa
Publication of PE20070317A1 publication Critical patent/PE20070317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

SE REFIERE A UN AGENTE DE UNION A ESCLEROSTINA O ANTICUERPO QUE CRUZA-BLOQUEA LA UNION DE LOS ANTICUERPOS Ab-A, Ab-B, Ab-C, Ab-D, Ab-1, Ab-2, ENTRE OTROS, A ESCLEROSTINA; Y SE UNE A UN EPITOPE T20.6 (NUDO DE CISTINA + 4 BRAZOS). DICHO ANTICUERPO TIENE AL MENOS UN 75% DE UN CDR QUE COMPRENDE: A) CDR-H1 ES LA SEQ ID Nº: 245 O SEQ ID Nº: 269; CDR-H2 ES LA SEQ ID Nº: 246 O SEQ ID Nº: 270 Y CDR-H3 ES LA SEQ ID Nº: 247 O SEQ ID Nº: 271; Y B) CDR-L1 ES LA SEQ ID Nº: 78 O SEQ ID Nº: 239; CDR-L2 ES LA SEQ ID Nº: 79 O SEQ ID Nº: 240 Y CDR-L3 ES LA SEQ ID Nº: 80 O SEQ ID Nº: 241. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. EL AGENTE DE UNION A ESCLEROSTINA O ANTICUERPO INCREMENTA LA FORMACION DE HUESO, DENSIDAD MINERAL OSEA, MASA OSEA, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE ACONDROPLASIA, DISPLASIA FIBROSA, PSEUDOARTROSIS, OSTEOARTRITIS, ENFERMEDAD DE PAGET JUVENIL
PE2006000459A 2005-05-03 2006-05-02 Agentes de union a esclerostina o fragmentos de esclerostina PE20070317A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67758305P 2005-05-03 2005-05-03
US77684706P 2006-02-24 2006-02-24
US78224406P 2006-03-13 2006-03-13
US79264506P 2006-04-17 2006-04-17
US11/411,003 US7592429B2 (en) 2005-05-03 2006-04-25 Sclerostin-binding antibody

Publications (1)

Publication Number Publication Date
PE20070317A1 true PE20070317A1 (es) 2007-04-27

Family

ID=36992590

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000459A PE20070317A1 (es) 2005-05-03 2006-05-02 Agentes de union a esclerostina o fragmentos de esclerostina

Country Status (42)

Country Link
US (7) US7592429B2 (es)
EP (7) EP2325199B1 (es)
JP (4) JP5462484B2 (es)
KR (4) KR101653122B1 (es)
CN (4) CN107446043A (es)
AR (1) AR053266A1 (es)
AU (2) AU2006242476B2 (es)
BR (2) BR122020023315B1 (es)
CA (2) CA2947080A1 (es)
CR (1) CR9524A (es)
CY (4) CY1114350T1 (es)
DK (3) DK1891101T3 (es)
EA (2) EA021539B1 (es)
ES (4) ES2689143T3 (es)
GE (2) GEP20166454B (es)
GT (1) GT200600186A (es)
HK (3) HK1151803A1 (es)
HR (3) HRP20211904T1 (es)
HU (3) HUE025530T2 (es)
IL (3) IL187106A (es)
LT (2) LT3670528T (es)
LU (1) LUC00151I2 (es)
MA (1) MA29528B1 (es)
ME (2) ME02247B (es)
MX (3) MX358705B (es)
MY (1) MY163480A (es)
NL (1) NL301034I2 (es)
NO (4) NO346914B1 (es)
NZ (2) NZ563539A (es)
PE (1) PE20070317A1 (es)
PH (1) PH12015501848A1 (es)
PL (3) PL2325199T3 (es)
PT (3) PT1891101E (es)
RS (3) RS62685B1 (es)
SG (1) SG10201403400UA (es)
SI (3) SI1891101T1 (es)
TN (1) TNSN07406A1 (es)
TW (5) TWI778444B (es)
UA (1) UA123695C2 (es)
UY (2) UY38207A (es)
WO (1) WO2006119107A2 (es)
ZA (1) ZA200709480B (es)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DK1721979T3 (da) 1998-11-27 2010-12-13 Ucb Pharma Sa Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en) * 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
BRPI0411552A (pt) * 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
ITTO20050905A1 (it) * 2005-12-23 2007-06-24 Univ Degli Studi Torino Leganti sintetici capaci di legare l'ocratossina e relativi usi
WO2008061013A2 (en) * 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2460828A3 (en) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
JP2010528002A (ja) 2006-12-29 2010-08-19 オステオジェネックス インコーポレイテッド Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
PT2131860E (pt) * 2007-03-20 2014-03-04 Lilly Co Eli Anticorpos antiesclerostina
WO2008134046A1 (en) * 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
US7977313B2 (en) * 2007-04-27 2011-07-12 Affinergy, Inc. Methods and compositions for promoting localization of pharmaceutically active agents to bone
WO2009029795A1 (en) * 2007-08-31 2009-03-05 Amgen Inc. Solid-state protein formulation
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
EP2628486A3 (en) 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
PL2708558T3 (pl) 2008-04-11 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
KR20110014607A (ko) * 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201008580A (en) * 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
PE20120211A1 (es) 2009-02-17 2012-03-24 Ucb Pharma Sa Anticuerpos que tienen especificidad por ox40 humana
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
CN102666875A (zh) * 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ603045A (en) 2010-04-07 2014-11-28 Abbvie Inc Tnf-alpha binding proteins
AU2011239935A1 (en) 2010-04-16 2012-11-08 Novartis Ag Methods and compositions for improving implant osseointegration
MX2012013268A (es) * 2010-05-14 2013-05-28 Amgen Inc Formulaciones de anticuerpos de alta concentracion.
US9403882B2 (en) * 2010-06-07 2016-08-02 Joshua Rabbani Sulfation of Wnt pathway proteins
US9493541B2 (en) * 2010-06-07 2016-11-15 Joshua Rabbani Antibodies specific for sulfated sclerostin
DK2575935T4 (da) 2010-06-07 2023-11-27 Amgen Inc Anordning til indgivelse af lægemiddel
US11167011B2 (en) 2010-06-07 2021-11-09 Enzo Biochem, Inc. Methods for treating bone loss using sclerostin peptides
US9617323B2 (en) 2010-06-07 2017-04-11 Joshua Rabbani Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
UY33702A (es) * 2010-11-02 2012-05-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
JP6147670B2 (ja) * 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
KR20140018315A (ko) 2011-03-25 2014-02-12 암젠 인크 항스클러로스틴 항체 결정 및 이의 제제
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
EP3404041B1 (en) 2011-04-19 2020-07-22 Amgen Inc. Method for treating osteoporosis
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
SI2703486T1 (en) 2011-04-25 2018-05-31 Daiichi Sankyo Company, Limited ANTI-B7-H3 PROTITELO
WO2012149246A1 (en) 2011-04-29 2012-11-01 Novartis Ag Methods of treating squamous cell carcinoma related applications
LT2739311T (lt) 2011-08-04 2018-06-11 Amgen Inc. Kaulų tarpų defektų gydymo būdas
US9987428B2 (en) 2011-10-14 2018-06-05 Amgen Inc. Injector and method of assembly
CN104203978A (zh) * 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
JP2014534218A (ja) 2011-10-24 2014-12-18 アッヴィ・インコーポレイテッド Ｔｎｆを標的とする免疫結合剤
BR112014009810A2 (pt) 2011-10-24 2017-04-25 Abbvie Inc imunoligantes biespecíficos dirigidos contra tnf e il-17
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
BR112014016108A2 (pt) * 2011-12-28 2018-09-11 Amgen Inc método de tratamento de perda óssea alvelar
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
AU2013285488B2 (en) * 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
RU2636043C2 (ru) 2012-11-01 2017-11-17 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20150290390A1 (en) 2012-11-21 2015-10-15 Amgen Inc. Drug delivery device
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
RS57840B1 (sr) * 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
LT3312195T (lt) * 2013-03-20 2020-01-10 Genzyme Corporation Nebaigtinės osteogenezės gydymo būdai
WO2014149357A1 (en) 2013-03-22 2014-09-25 Amgen Inc. Injector and method of assembly
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3789064A1 (en) 2013-10-24 2021-03-10 Amgen, Inc Injector and method of assembly
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CN110642944B (zh) * 2014-03-07 2021-06-11 神州细胞工程有限公司 一种中和人感染h7n9甲型流感病毒的抗体及其用途
US10267806B2 (en) 2014-04-04 2019-04-23 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
SG10201811702TA (en) 2014-05-07 2019-01-30 Amgen Inc Autoinjector with shock reducing elements
MX2016014761A (es) 2014-05-16 2017-05-25 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
CA2948003C (en) 2014-06-03 2023-06-27 Amgen Inc. Drug delivery system and method of use
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
EA202191513A1 (ru) 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
JP6716566B2 (ja) 2014-12-19 2020-07-01 アムジエン・インコーポレーテツド 近接センサ付き薬物送達装置
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3258988B1 (en) 2015-02-17 2019-08-28 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
RS61158B1 (sr) * 2015-03-13 2021-01-29 Jiangsu Hengrui Medicine Co Anti-sklerostin antitelo, antigen vezujući fragment i njegova medicinska upotreba
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EA038973B1 (ru) 2015-07-06 2021-11-17 Ридженерон Фармасьютикалз, Инк. Полиспецифические антигенсвязывающие молекулы и их применения
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
EP3219727B1 (en) * 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (en) 2016-07-01 2019-05-08 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018031454A1 (en) 2016-08-08 2018-02-15 Amgen Inc. Method of improving connective tissue attachment using anti-sclerostin antibodies
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
CN109642899B (zh) * 2016-08-31 2024-03-08 荣研化学株式会社 使用由不同的方式固定化抗原的抗原负载不溶性载体粒子的抗体测定法、抗体测定用试剂
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
JP7136468B2 (ja) 2016-11-08 2022-09-13 ユニバーシティ オブ マイアミ 抗セクレトグラニンｉｉｉ（ｓｃｇ３）抗体およびその使用
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
ES2862922T3 (es) 2016-12-21 2021-10-08 Mereo Biopharma 3 Ltd Uso de anticuerpos antiesclerostina en el tratamiento de la osteogénesis imperfecta
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
EP3574010A4 (en) * 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
CA3052204A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
MX2019010544A (es) 2017-03-06 2019-10-21 Amgen Inc Dispositivo de administracion de farmacos con caracteristica de prevencion de la activacion.
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
US20200131518A1 (en) 2017-03-14 2020-04-30 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN110446512B (zh) 2017-03-28 2022-03-18 美国安进公司 柱塞杆和注射器组件系统以及方法
CA3059468A1 (en) * 2017-04-27 2018-11-01 Tesaro, Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
AU2018258676A1 (en) 2017-04-28 2019-10-31 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11904143B2 (en) 2017-06-08 2024-02-20 Amgen Inc. Torque driven drug delivery device
CA3063920A1 (en) 2017-06-22 2018-12-27 Amgen Inc. Device activation impact/shock reduction
EP3641861A1 (en) 2017-06-23 2020-04-29 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
UA127219C2 (uk) 2017-07-27 2023-06-14 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, що містить анти-sost антитіло, та її застосування
EP3662287B1 (en) 2017-08-01 2024-02-28 Amgen Inc. Systems and methods for real time preparation of a polypeptide sample for anaylsis with mass spectrometry
CA3071636A1 (en) 2017-08-01 2019-02-07 Amgen Inc. Systems and methods for performing a real-time glycan assay of a sample
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019051047A1 (en) 2017-09-07 2019-03-14 University Of Florida Research Foundation, Inc. CHIMERIC ANTIGEN RECEPTOR T-LYMPHOCYTES EXPRESSING THE INTERLEUKIN-8 RECEPTOR
EP3681528A4 (en) 2017-09-13 2021-07-21 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF THE APOPTOSIS INHIBITOR OF MACROPHAGES
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
US11813426B2 (en) 2017-10-06 2023-11-14 Amgen Inc. Drug delivery device including seal member for needle of syringe
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
MA50527A (fr) 2017-11-03 2020-09-09 Amgen Inc Système et approches pour stériliser un dispositif d'administration de médicament
US20200338271A1 (en) 2017-11-06 2020-10-29 Amgen Inc. Fill-finish assemblies and related methods
JP2021501616A (ja) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド 配置及び流量検出を備える薬物送達デバイス
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
AU2018368338A1 (en) 2017-11-16 2020-04-09 Amgen Inc. Autoinjector with stall and end point detection
JP2021516672A (ja) 2018-03-13 2021-07-08 アムジエン・インコーポレーテツド 質量分光測定分析のためのトリプシン耐性ポリペプチドを調製するための方法
WO2019178280A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
EP3775251A1 (en) 2018-03-26 2021-02-17 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
EP3774879A1 (en) 2018-03-30 2021-02-17 Amgen Inc. C-terminal antibody variants
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
EP3817770A2 (en) 2018-07-02 2021-05-12 Amgen Inc. Anti-steap1 antigen-binding protein
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MX2021000748A (es) 2018-07-24 2021-03-26 Amgen Inc Dispositivos de suministro para administrar farmacos.
US20210228797A1 (en) 2018-07-31 2021-07-29 Amgen Inc. Fluid path assembly for a drug delivery device
SG11202100952QA (en) 2018-08-10 2021-02-25 Amgen Inc Method of preparing an antibody pharmaceutical formulation
AU2019347710A1 (en) 2018-09-24 2021-02-04 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (en) 2018-09-28 2021-08-04 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
CN112805048B (zh) 2018-10-02 2023-09-22 安进公司 具有内部力传递的用于药物递送的注射系统
MA53818A (fr) 2018-10-05 2022-01-12 Amgen Inc Dispositif d'administration de médicament ayant un indicateur de dose
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
CN117138169A (zh) 2018-10-15 2023-12-01 安进公司 药物递送装置
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US20220146413A1 (en) 2018-12-14 2022-05-12 Amgen Inc. System suitability method for use with protein concentration determination by slope
WO2020168156A1 (en) 2019-02-14 2020-08-20 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
CA3127817A1 (en) 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
EP3935396A1 (en) 2019-03-04 2022-01-12 Amgen Inc. In vivo reversibility of high molecular weight species
CN109897105B (zh) * 2019-03-22 2022-05-20 天承南运(天津)科技有限公司 Ev71病毒的单克隆抗体、其制备方法及其检测试纸条
US20220187398A1 (en) 2019-03-27 2022-06-16 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
US20220260584A1 (en) 2019-06-05 2022-08-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
US20220275073A1 (en) 2019-08-12 2022-09-01 Amgen Inc. Anti-Sclerostin Antibody Formulations
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
JP2022549329A (ja) 2019-09-26 2022-11-24 アムジェン インコーポレイテッド 抗体組成物を製造する方法
WO2021222944A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
CN111537737B (zh) * 2020-05-18 2023-05-12 巴迪泰（广西）生物科技有限公司 降钙素原与c-反应蛋白联合检测试剂盒
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3195365A1 (en) 2020-09-18 2022-03-24 Amgen Inc. Methods of processing a sample for peptide mapping analysis
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
CA3200262A1 (en) 2020-11-05 2022-05-12 Amgen Inc. Materials and methods for protein processing
KR102255372B1 (ko) 2020-11-24 2021-05-25 (주)발맥스기술 간편 제작 설치 가능 bog 열교환장치
CN117320964A (zh) 2021-05-21 2023-12-29 美国安进公司 优化药物容器的灌装方案的方法
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
CA3233279A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023086793A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
WO2023179791A1 (en) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Treatment of musculoskeletal disorders
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) 1861-04-09 Coffee-pot
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) * 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
JPS5955608A (ja) * 1982-09-24 1984-03-30 Hitachi Ltd 増幅器
US4543439A (en) * 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) * 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) * 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) * 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) * 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
CA2094608A1 (en) 1990-10-22 1992-04-23 John D. Taylor Dna construct for providing rna therapy
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0628639B1 (en) * 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5837458A (en) * 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5863738A (en) 1994-04-29 1999-01-26 Creative Biomolecules, Inc. Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
US5738868A (en) * 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
AU725238B2 (en) * 1996-05-22 2000-10-12 Viventia Biotech Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
AU729035B2 (en) * 1997-06-12 2001-01-25 Novartis Ag Artificial antibody polypeptides
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AU8555798A (en) 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) * 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
GB9818881D0 (en) 1998-08-28 1998-10-21 Glaxo Group Ltd Compounds
US6544485B1 (en) * 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
DK1721979T3 (da) * 1998-11-27 2010-12-13 Ucb Pharma Sa Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
CN1345334A (zh) 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
AU4851900A (en) 1999-06-09 2000-12-28 Genentech Inc. Compositions and methods for the treatment of tumor
JP4141095B2 (ja) 1999-10-29 2008-08-27 三洋電機株式会社 半導体装置とその製造方法
AU2001241968B2 (en) 2000-03-02 2005-09-15 Amgen Inc. Chordin-like-2 molecules and uses thereof
WO2001092308A2 (en) * 2000-06-01 2001-12-06 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
US20040132021A1 (en) 2000-06-19 2004-07-08 Wendy Balemans Osteolevin gene polymorphisms
EP1341814A2 (en) 2000-09-01 2003-09-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) * 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
EP1436329A4 (en) * 2001-09-20 2005-04-27 Alexion Pharma Inc ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
AUPR837201A0 (en) 2001-10-19 2001-11-15 BUKILIC, Aleksandar Method and apparatus for cleaning and disinfecting a toothbrush
EP1451560B1 (en) 2001-12-06 2017-11-29 BioControl Systems, Inc. Sample collection and testing system
US20030186915A1 (en) * 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
JP4662714B2 (ja) * 2002-03-01 2011-03-30 セルテック アール アンド ディー インコーポレイテッド 骨密度を増減させる方法
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
FR2838379B1 (fr) 2002-04-12 2005-06-24 Valeo Climatisation Dispositif de purification de l'air de l'habitacle d'un vehicule automobile
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
JP4976653B2 (ja) 2002-11-01 2012-07-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス 免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法
DE10255152A1 (de) 2002-11-26 2004-06-03 Von Langen Ursula Lang Schadstoffsauger
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en) * 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
ATE540977T1 (de) 2003-03-14 2012-01-15 Ucb Mfg Inc Komplex von sclerostin mit noggin oder chordin, und modulatoren der bildung dieses komplexes
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
BRPI0411552A (pt) 2003-06-16 2006-08-01 Celltech R & D Inc anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
WO2005018912A1 (de) * 2003-07-21 2005-03-03 Alpla-Werke Alwin Lehner Gmbh & Co. Kg Verfahren zur herstellung eines preformlings für kunststoffflaschen
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
WO2006015373A2 (en) 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP1981910B1 (en) 2006-01-13 2013-06-26 A Chan Holding B.V. Method for identifying inhibitor of the glypican-sclerostin interaction
EP2460828A3 (en) 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
JP2010528002A (ja) 2006-12-29 2010-08-19 オステオジェネックス インコーポレイテッド Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
JP2010526766A (ja) 2007-02-02 2010-08-05 ノバルティス アーゲー 骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
PT2131860E (pt) 2007-03-20 2014-03-04 Lilly Co Eli Anticorpos antiesclerostina
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
PL2567709T3 (pl) 2007-11-02 2018-06-29 Novartis Ag Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
EP2628486A3 (en) 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
MX2012013268A (es) * 2010-05-14 2013-05-28 Amgen Inc Formulaciones de anticuerpos de alta concentracion.
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
TWI636993B (zh) 2010-10-27 2018-10-01 安美基公司 Ｄｋｋ１抗體及使用方法
US9133272B2 (en) * 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
KR20140018315A (ko) * 2011-03-25 2014-02-12 암젠 인크 항스클러로스틴 항체 결정 및 이의 제제
LT2739311T (lt) * 2011-08-04 2018-06-11 Amgen Inc. Kaulų tarpų defektų gydymo būdas
BR112014016108A2 (pt) * 2011-12-28 2018-09-11 Amgen Inc método de tratamento de perda óssea alvelar
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3774879A1 (en) * 2018-03-30 2021-02-17 Amgen Inc. C-terminal antibody variants

Also Published As

Publication number Publication date
ES2537278T3 (es) 2015-06-05
AU2006242431B2 (en) 2012-11-08
MX358705B (es) 2018-08-31
TWI778444B (zh) 2022-09-21
CR9524A (es) 2008-05-21
AU2006242476B2 (en) 2012-05-31
CN107446043A (zh) 2017-12-08
EP3670528A1 (en) 2020-06-24
KR20080011420A (ko) 2008-02-04
EA200702402A1 (ru) 2008-04-28
TW201323438A (zh) 2013-06-16
KR101624809B1 (ko) 2016-05-26
GEP20166454B (en) 2016-04-11
ES2689143T3 (es) 2018-11-08
SI3670528T1 (sl) 2022-01-31
WO2006119107A9 (en) 2007-09-20
PL2325199T3 (pl) 2015-08-31
EP1891101A2 (en) 2008-02-27
IL187106A (en) 2015-10-29
CY2020009I1 (el) 2020-11-25
TWI494320B (zh) 2015-08-01
UA123695C2 (uk) 2021-05-19
CY1114350T1 (el) 2016-08-31
US20160168241A1 (en) 2016-06-16
CN103819558B (zh) 2016-08-24
EP2325200A1 (en) 2011-05-25
LTPA2020506I1 (lt) 2020-04-27
EP2336163A1 (en) 2011-06-22
PL3670528T3 (pl) 2022-01-31
US20130203965A1 (en) 2013-08-08
EP2325199A1 (en) 2011-05-25
TW200716667A (en) 2007-05-01
US20070110747A1 (en) 2007-05-17
JP5789652B2 (ja) 2015-10-07
HRP20150597T1 (hr) 2015-09-11
CN101287756B (zh) 2014-06-25
US20130121997A1 (en) 2013-05-16
UY38207A (es) 2020-11-30
MX2007013759A (es) 2008-04-29
LTC1891101I2 (lt) 2020-09-25
CY1124802T1 (el) 2022-11-25
ES2902548T3 (es) 2022-03-28
HK1108705A1 (en) 2008-05-16
PT2325199E (pt) 2015-07-10
CA2607197A1 (en) 2006-11-09
HUE057097T2 (hu) 2022-04-28
BRPI0610197A2 (pt) 2010-06-01
BRPI0610197B1 (pt) 2021-05-11
US9296812B2 (en) 2016-03-29
BRPI0610197B8 (pt) 2021-05-25
DK2325199T3 (da) 2015-05-26
NO20201120A1 (no) 2008-01-30
CN103819558A (zh) 2014-05-28
US20090304713A1 (en) 2009-12-10
PT3670528T (pt) 2021-12-09
JP2014012001A (ja) 2014-01-23
NO345294B1 (no) 2020-11-30
WO2006119107A2 (en) 2006-11-09
KR101450888B1 (ko) 2014-10-16
RS62685B1 (sr) 2021-12-31
TWI712613B (zh) 2020-12-11
AR053266A1 (es) 2007-04-25
UY29514A1 (es) 2006-11-30
NZ591636A (en) 2012-10-26
JP2014061000A (ja) 2014-04-10
PL1891101T3 (pl) 2013-11-29
JP5391360B2 (ja) 2014-01-15
ZA200709480B (en) 2010-07-28
CA2947080A1 (en) 2006-11-09
US11939372B2 (en) 2024-03-26
GEP20125594B (en) 2012-08-10
EP3670528B1 (en) 2021-09-08
HK1198444A1 (en) 2015-04-24
EP2264063B1 (en) 2018-06-27
AU2006242476A1 (en) 2006-11-09
RS52919B (en) 2014-02-28
NO2021014I1 (no) 2021-03-24
IL224967B (en) 2019-03-31
AU2006242431A1 (en) 2006-11-09
TW201741332A (zh) 2017-12-01
ES2412857T3 (es) 2013-07-12
EP2264063A1 (en) 2010-12-22
NZ563539A (en) 2011-04-29
NO20230084A1 (no) 2008-01-30
HRP20211904T1 (hr) 2022-03-04
JP2013249303A (ja) 2013-12-12
MX2018005512A (es) 2021-11-16
US20110097342A1 (en) 2011-04-28
SI1891101T1 (sl) 2013-10-30
CY1116525T1 (el) 2017-03-15
CN103435698B (zh) 2018-08-31
MA29528B1 (fr) 2008-06-02
ME02085B (me) 2014-02-28
HRP20130803T1 (hr) 2013-11-08
IL224968B (en) 2018-03-29
EP3985015A1 (en) 2022-04-20
US8637643B2 (en) 2014-01-28
JP2008539726A (ja) 2008-11-20
CY2020009I2 (el) 2020-11-25
ME02247B (me) 2015-10-30
HUS2000007I1 (hu) 2020-03-30
US7592429B2 (en) 2009-09-22
SI2325199T1 (sl) 2015-07-31
EP1891101B1 (en) 2013-05-22
RS54049B1 (en) 2015-10-30
LT3670528T (lt) 2021-12-27
EA021539B1 (ru) 2015-07-30
CN103435698A (zh) 2013-12-11
HK1151803A1 (en) 2012-02-10
SG10201403400UA (en) 2014-10-30
CN101287756A (zh) 2008-10-15
IL187106A0 (en) 2008-02-09
KR101653122B1 (ko) 2016-08-31
KR20150117302A (ko) 2015-10-19
NO346914B1 (no) 2023-02-27
LUC00151I2 (es) 2021-02-15
KR20130126752A (ko) 2013-11-20
BR122020023315B1 (pt) 2021-06-08
NO20076046L (no) 2008-01-30
US8383801B2 (en) 2013-02-26
HUE025530T2 (en) 2016-04-28
JP5409952B2 (ja) 2014-02-05
US7872106B2 (en) 2011-01-18
EP2325199B1 (en) 2015-03-04
EA037044B1 (ru) 2021-01-29
GT200600186A (es) 2007-02-09
WO2006119107A3 (en) 2006-12-28
CA2607197C (en) 2016-12-13
TW202108605A (zh) 2021-03-01
EP1891101B8 (en) 2013-06-26
LUC00151I1 (es) 2020-03-16
EA201400933A1 (ru) 2015-04-30
TW202323271A (zh) 2023-06-16
DK3670528T3 (da) 2021-12-06
TNSN07406A1 (en) 2009-03-17
NL301034I2 (nl) 2020-05-13
JP5462484B2 (ja) 2014-04-02
DK1891101T3 (da) 2013-08-26
PH12015501848A1 (en) 2020-07-06
PT1891101E (pt) 2013-08-23
MY163480A (en) 2017-09-15
US10562964B2 (en) 2020-02-18
KR20140037293A (ko) 2014-03-26
US20200048338A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
PE20070317A1 (es) Agentes de union a esclerostina o fragmentos de esclerostina
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
RU2363706C2 (ru) Антитела к рецептору инсулиноподобного фактора роста i и их применение
JP2017536341A5 (es)
NZ585559A (en) Humanized antibodies against tl1a
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
NZ622583A (en) Protein formulations and methods of making same
RU2013155906A (ru) Антитела анти-angptl3 и их применение
NZ568403A (en) CD20-specific antibodies and methods of employing same
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
RS54452B1 (en) INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ625807A (en) Human anti-b7rp1 neutralizing antibodies
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
PE20120211A1 (es) Anticuerpos que tienen especificidad por ox40 humana
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
PE20070998A1 (es) Moleculas de anticuerpo que tienen especificidad para la il-6-humana
JP2003527861A5 (es)
NZ610153A (en) Novel anti-dr5 antibody
NZ596712A (en) Anti cxcr4 antibodies for the treatment of hiv

Legal Events

Date Code Title Description
FG Grant, registration